{"id":49300,"date":"2022-10-06T22:01:42","date_gmt":"2022-10-06T20:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/"},"modified":"2022-10-06T22:01:42","modified_gmt":"2022-10-06T20:01:42","slug":"teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/","title":{"rendered":"Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022"},"content":{"rendered":"
\n

TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2022 financial results on Thursday, November 3, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.\n<\/p>\n

<\/a><\/p>\n

\nIn order to participate, please register in advance here<\/a><\/b><\/span> to obtain a local or toll-free phone number and your personal pin.\n<\/p>\n

\nA live webcast of the call will be available on Teva’s website at: http:\/\/ir.tevapharm.com\/<\/a>.\n<\/p>\n

\nFollowing the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva’s website.\n<\/p>\n

\nAbout Teva<\/b>\n<\/p>\n

\nTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people\u2019s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com<\/a>.\n<\/p>\n

\nCautionary Note Regarding Forward-Looking Statements<\/b>\n<\/p>\n

\nThis document and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management\u2019s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our substantial indebtedness; our business and operations in general including: uncertainty regarding the COVID-19 pandemic and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the sections captioned \u201cRisk Factors.\u201d Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nIR Contacts
\n
<\/b>\n<\/p>\n

\nRan Meir
\n
(267) 468-4475
\n\n<\/p>\n

\nYael Ashman
\n
+972 (3) 914 8262
\n\n<\/p>\n

\nPR Contacts<\/b>\n<\/p>\n

\nKelley Dougherty
\n
(973) 832-2810
\n\n<\/p>\n

\nEden Klein
\n
+972 (3) 906 2645\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2022 financial results on Thursday, November 3, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49300","6":"format-standard","7":"category-industry"},"yoast_head":"\nTeva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2022 financial results on Thursday, November 3, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-06T20:01:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221006005712\/en\/739014\/21\/teva_RGB_JPEG.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022\",\"datePublished\":\"2022-10-06T20:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\\\/\"},\"wordCount\":464,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221006005712\\\/en\\\/739014\\\/21\\\/teva_RGB_JPEG.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\\\/\",\"name\":\"Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221006005712\\\/en\\\/739014\\\/21\\\/teva_RGB_JPEG.jpg\",\"datePublished\":\"2022-10-06T20:01:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221006005712\\\/en\\\/739014\\\/21\\\/teva_RGB_JPEG.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221006005712\\\/en\\\/739014\\\/21\\\/teva_RGB_JPEG.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/","og_locale":"en_US","og_type":"article","og_title":"Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022 - Pharma Trend","og_description":"TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2022 financial results on Thursday, November 3, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-06T20:01:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221006005712\/en\/739014\/21\/teva_RGB_JPEG.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022","datePublished":"2022-10-06T20:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/"},"wordCount":464,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221006005712\/en\/739014\/21\/teva_RGB_JPEG.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/","url":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/","name":"Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221006005712\/en\/739014\/21\/teva_RGB_JPEG.jpg","datePublished":"2022-10-06T20:01:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221006005712\/en\/739014\/21\/teva_RGB_JPEG.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221006005712\/en\/739014\/21\/teva_RGB_JPEG.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/teva-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-at-8-a-m-et-on-november-3-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49300"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49300\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}